Normalize with Mytesi
1 in 5 people living with HIV suffer from chronic diarrhea. Mytesi is the only FDA-approved treatment
that can provide sustained relief from noninfectious diarrhea.1
Mytesi can effectively reduce noninfectious diarrhea. It is a non-opiate derivative and
has a very low risk of causing constipation.
No significant drug interactions
Mytesi is not systemically absorbed into
the bloodstream and does not interact
with other medications.
Indicated for HIV-positive patients
Mytesi does not affect viral load, and is effective and safe to use long-term to provide symptomatic relief of HIV-related diarrhea.
Normalizing Your Gut
Chloride ion channels in the gastrointestinal (GI) tract maintain a balance of salts—including chloride (Cl–) ions—and water that allows normal stool formation.
Chloride ion (salt)
Chloride ion channel
Improper function of ion channels leads to an excess of salts and water within the GI tract, disrupting the normal balance and resulting in diarrhea.
Mytesi restores the balance of salts and water in the GI tract by normalizing improperly functioning chloride ion (Cl–) channels.
After 3-4 weeks, Mytesi can reduce the severity of watery bowel movements and provide sustained long term relief 1. In nonclincal studies, crofelemer, the active ingredient in Mytesi, does not slow down gut motility and is therefore less likely to cause constipation.
Is Mytesi Right for Me?
- Gehrig M, Clay P, Perry R, et al. Actual versus perceived use of pharmacokinetic (primarily absorption) influential OTC agents and ART tolerability in a nationwide matched cohort of HIV patients and their healthcare providers. Poster abstract presented at: ID Week 2016; October 26-30, 2016; New Orleans, LA.
- MacArthur RD, Clay P, Blick G, et al. Long-Term Crofelemer Provides Clinically Relevant Reductions in HIV-Related Diarrhea. Poster presented at: 9th IAS Conference on
HIV Science (IAS 2017); 2017 July 23-26; Paris, France.